Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
JANX Stock Summary
Top 10 Correlated ETFs
JANX
In the News
Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)
Cantor Fitzgerald initiated coverage on Janux Therapeutics Inc JANX, citing the company's TRACTr/TRACir platform to target numerous tumor antigens and cancer types.
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Viking Therapeutics and Janux Therapeutics are flying high on the back of positive data readouts. However, there is a long road ahead and plenty of potential risks for both of these mid-cap biotechs.
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
Janux Therapeutics just reported some phenomenal early Phase 1 data. It still needs to confirm the value of its programs and platform.
5 Stocks That More Than Doubled in February
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
Recent Price Trend in Janux Therapeutics, Inc. (JANX) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics, Inc. (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Janux Therapeutics, Inc. has positive preliminary results released from phase 1a study, using JANX007 for the treatment of patients with advanced or metastatic castration-resistant prostate cancer. With positive single-agent activity of JANX007 observed in patients with metastatic castration-resistant prostate cancer, potential to advance combination therapy with PSMA targeting agent XTANDI. It is expected that the global prostate cancer therapeutics market could reach $28.5 billion by 2032.
Why Is Janux Therapeutics (JANX) Stock Up 108% Today?
Janux Therapeutics (NASDAQ: JANX ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company posted interim results from two studies. According to a press release from Janux Therapeutics, both JANX007 and JANX008 are showing encouraging efficacy and safety data in their clinical trials.
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
Janux Therapeutics, Inc. (JANX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Does Janux Therapeutics, Inc. (JANX) Have the Potential to Rally 205.5% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 205.5% in Janux Therapeutics, Inc. (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
JANX Financial details
JANX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.15 | 0.21 | 0.18 | |
Net income per share | -0.66 | -0.42 | -1.38 | -1.31 | -1.32 | |
Operating cash flow per share | -0.6 | -0.35 | -0.72 | -1.04 | -1.15 | |
Free cash flow per share | -0.6 | -0.35 | -0.78 | -1.19 | -1.19 | |
Cash per share | 0.1 | 0.63 | 15.94 | 7.89 | 7.82 | |
Book value per share | -1.24 | -1.17 | 15.57 | 7.73 | 7.82 | |
Tangible book value per share | -1.24 | -1.17 | 15.57 | 7.73 | 7.82 | |
Share holders equity per share | -1.24 | -1.17 | 15.57 | 7.73 | 7.82 | |
Interest debt per share | 1.28 | 0.08 | 0.01 | 0.71 | 0.56 | |
Market cap | 161.34M | 313.69M | 464.25M | 546.16M | 472.29M | |
Enterprise value | 164.68M | 305.87M | 428.86M | 520.03M | 477.63M | |
P/E ratio | -38.08 | -59.69 | -14.26 | -10.09 | -8.1 | |
Price to sales ratio | 0 | 0 | 127.65 | 63.42 | 58.43 | |
POCF ratio | -42.15 | -71.8 | -27.35 | -12.72 | -9.34 | |
PFCF ratio | -42.15 | -71.8 | -25.15 | -11.06 | -9.01 | |
P/B Ratio | -20.31 | -21.43 | 1.27 | 1.7 | 1.37 | |
PTB ratio | -20.31 | -21.43 | 1.27 | 1.7 | 1.37 | |
EV to sales | 0 | 0 | 117.92 | 60.38 | 59.09 | |
Enterprise value over EBITDA | -43.74 | -46.59 | -13.02 | -7.75 | -6.72 | |
EV to operating cash flow | -43.02 | -70.01 | -25.26 | -12.12 | -9.44 | |
EV to free cash flow | -43.02 | -70.01 | -23.23 | -10.53 | -9.11 | |
Earnings yield | -0.03 | -0.02 | -0.07 | -0.1 | -0.12 | |
Free cash flow yield | -0.02 | -0.01 | -0.04 | -0.09 | -0.11 | |
Debt to equity | -1.01 | -0.05 | 0 | 0.08 | 0.07 | |
Debt to assets | 11.78 | 0.05 | 0 | 0.07 | 0.06 | |
Net debt to EBITDA | -0.89 | 1.19 | 1.07 | 0.39 | -0.08 | |
Current ratio | 0.14 | 5.05 | 29.46 | 20.14 | 26.8 | |
Interest coverage | -16.18 | -23.51 | 0 | -16.64 | 0 | |
Income quality | 0.96 | 0.64 | 0.52 | 0.68 | 0.87 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 2.84 | 2.58 | 3.23 | |
Research and developement to revenue | 0 | 0 | 7.21 | 6.21 | 6.79 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.09 | 0.15 | 0.04 | |
Capex to revenue | 0 | 0 | -0.41 | -0.75 | -0.23 | |
Capex to depreciation | 0 | 0 | -13.12 | -7.66 | -0.95 | |
Stock based compensation to revenue | 0 | 0 | 1.9 | 2 | 2.47 | |
Graham number | 4.29 | 3.34 | 22.02 | 15.07 | 15.27 | |
ROIC | -76.74 | 0.27 | -0.09 | -0.16 | -0.19 | |
Return on tangible assets | -6.24 | -0.32 | -0.09 | -0.15 | -0.15 | |
Graham Net | -1.24 | -1.37 | 15.36 | 6.85 | 7.01 | |
Working capital | -3.97M | 12.88M | 364.22M | 315.93M | 336.21M | |
Tangible asset value | -7.94M | -14.64M | 366.33M | 320.74M | 344.35M | |
Net current asset value | -7.97M | -14.79M | 363.52M | 289.17M | 313.18M | |
Invested capital | -1.01 | -0.05 | 0 | 0.08 | 0.07 | |
Average receivables | 0 | 4M | 4.1M | 450K | 1.45M | |
Average payables | 0 | 347.5K | 1.44M | 2.31M | 2.29M | |
Average inventory | 0 | 0 | -100K | -450K | -1.45M | |
Days sales outstanding | 0 | 0 | 20.07 | 29.67 | 99.34 | |
Days payables outstanding | 16.24K | 12.02K | 7.94K | 937.02 | 452.56 | |
Days of inventory on hand | 0 | 0 | -646.02 | -303.8 | -410.74 | |
Receivables turnover | 0 | 0 | 18.19 | 12.3 | 3.67 | |
Payables turnover | 0.02 | 0.03 | 0.05 | 0.39 | 0.81 | |
Inventory turnover | 0 | 0 | -0.57 | -1.2 | -0.89 | |
ROE | 0.53 | 0.36 | -0.09 | -0.17 | -0.17 | |
Capex per share | 0 | 0 | -0.06 | -0.16 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.07 | 0.05 | 0.03 | 0.06 | 0.05 | |
Net income per share | -0.27 | -0.42 | -0.42 | -0.25 | -0.25 | |
Operating cash flow per share | -0.29 | -0.33 | -0.36 | -0.26 | -0.21 | |
Free cash flow per share | -0.34 | -0.34 | -0.37 | -0.27 | -0.22 | |
Cash per share | 7.86 | 7.59 | 7.25 | 7.65 | 7.37 | |
Book value per share | 7.71 | 7.45 | 7.16 | 7.63 | 7.38 | |
Tangible book value per share | 7.71 | 7.45 | 7.16 | 7.63 | 7.38 | |
Share holders equity per share | 7.71 | 7.45 | 7.16 | 7.63 | 7.38 | |
Interest debt per share | 0.66 | 0.53 | 0.6 | 0.54 | 0.53 | |
Market cap | 547.66M | 505.34M | 496.6M | 460.74M | 500.92M | |
Enterprise value | 521.54M | 500.53M | 488.12M | 468.48M | 506.25M | |
P/E ratio | -12.16 | -7.24 | -7.09 | -9.96 | -10.65 | |
Price to sales ratio | 192.5 | 246.75 | 469.82 | 183.05 | 203.54 | |
POCF ratio | -45.97 | -36.33 | -32.99 | -39.35 | -50.59 | |
PFCF ratio | -39.21 | -35.6 | -31.76 | -37.83 | -48.09 | |
P/B Ratio | 1.71 | 1.62 | 1.66 | 1.32 | 1.45 | |
PTB ratio | 1.71 | 1.62 | 1.66 | 1.32 | 1.45 | |
EV to sales | 183.32 | 244.4 | 461.8 | 186.13 | 205.71 | |
Enterprise value over EBITDA | -28.55 | -24.68 | -24.07 | -29.63 | -32.44 | |
EV to operating cash flow | -43.78 | -35.98 | -32.42 | -40.01 | -51.13 | |
EV to free cash flow | -37.34 | -35.26 | -31.22 | -38.47 | -48.6 | |
Earnings yield | -0.02 | -0.03 | -0.04 | -0.03 | -0.02 | |
Free cash flow yield | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | |
Debt to equity | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | |
Debt to assets | 0.07 | 0.07 | 0.07 | 0.06 | 0.06 | |
Net debt to EBITDA | 1.43 | 0.24 | 0.42 | -0.49 | -0.34 | |
Current ratio | 20.14 | 19.95 | 17.28 | 24.55 | 26.8 | |
Interest coverage | -8.3 | 6.19 | 0 | 0 | 0 | |
Income quality | 0.74 | 0.8 | 0.86 | 1.01 | 0.84 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2 | 3.16 | 6.51 | 2.56 | 2.58 | |
Research and developement to revenue | 5.42 | 7.75 | 14.12 | 4.72 | 4.97 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.17 | 0.02 | 0.04 | 0.04 | 0.05 | |
Capex to revenue | -0.72 | -0.14 | -0.55 | -0.19 | -0.21 | |
Capex to depreciation | -5.1 | -0.63 | -1.23 | -0.94 | -0.97 | |
Stock based compensation to revenue | 1.48 | 2.67 | 5.2 | 1.81 | 1.82 | |
Graham number | 6.86 | 8.37 | 8.21 | 6.59 | 6.47 | |
ROIC | -0.03 | -0.05 | -0.06 | -0.04 | -0.04 | |
Return on tangible assets | -0.03 | -0.05 | -0.05 | -0.03 | -0.03 | |
Graham Net | 6.83 | 6.6 | 6.25 | 6.83 | 6.61 | |
Working capital | 315.93M | 305.29M | 291.4M | 340.72M | 336.21M | |
Tangible asset value | 320.74M | 311.26M | 299.47M | 348.95M | 344.35M | |
Net current asset value | 289.17M | 279.71M | 267.27M | 317.29M | 313.18M | |
Invested capital | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | |
Average receivables | 600K | 725K | 1.13M | 1.6M | 1.95M | |
Average payables | 2.51M | 2.11M | 1.98M | 2.21M | 2.46M | |
Average inventory | -350K | -350K | -750K | -1.6M | -1.95M | |
Days sales outstanding | 22.14 | 32.96 | 127.72 | 60.79 | 80.46 | |
Days payables outstanding | 482.16 | 407.48 | 364.97 | 450.9 | 410.85 | |
Days of inventory on hand | -156.33 | 0 | -286.62 | -306 | -372.88 | |
Receivables turnover | 4.06 | 2.73 | 0.7 | 1.48 | 1.12 | |
Payables turnover | 0.19 | 0.22 | 0.25 | 0.2 | 0.22 | |
Inventory turnover | -0.58 | 0 | -0.31 | -0.29 | -0.24 | |
ROE | -0.04 | -0.06 | -0.06 | -0.03 | -0.03 | |
Capex per share | -0.05 | -0.01 | -0.01 | -0.01 | -0.01 |
JANX Frequently Asked Questions
What is Janux Therapeutics, Inc. stock symbol ?
Janux Therapeutics, Inc. is a US stock , located in La jolla of Ca and trading under the symbol JANX
What is Janux Therapeutics, Inc. stock quote today ?
Janux Therapeutics, Inc. stock price is $37.595 today.
Is Janux Therapeutics, Inc. stock public?
Yes, Janux Therapeutics, Inc. is a publicly traded company.